GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

Months after causing safety concerns that led the FDA to hit a related trial with a clinical hold, a phase 2 trial of ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Teos Therapeutics is throwing in the towel. | iTeos Therapeutics is throwing in the towel. Two weeks after axing its ...

An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), ...

AbbVie is looking south to boost its community-based clinical trials. | AbbVie is looking south to boost its community-based clinical trials. The Chicago-area pharma giant is partnering with Nashville ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

Five people have been charged for allegedly participating in an insider trading scheme tied to Novartis’ $3.2 billion ...

Almost all the patients with depression who received Gilgamesh Pharmaceuticals’ psychedelic drug candidate went into ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Boundless Bio is in a bind. A phase 1/2 trial has revealed the shortcomings of Boundless’ lead candidate, prompting the ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...